TOP HEADLINES

Featured Story

  • Hospira recall of ketorolac now close to 40 million vials

    After recalling 18 million vials last January of a painkiller commonly used in surgery, sterile injectables maker Hospira indicated that it was on top of the problem. But the company now says new manufacturing issues have cropped up that have led it to recall more than 20.7 million more vials of ketorolac, a drug on the FDA shortage list.

Androxy returns to market after 9-month lapse

Upsher-Smith had to quit shipping fluoxymesterone tablets last fall when its supplier quit making the API for Androxy. The problem was that Upsher-Smith is the only supplier in the U.S. for the drug, which is used to treat breast cancer in women and low testosterone in men. Now Upsher-Smith says Androxy is back.

Teva expands recall of cancer drug Adrucil

Teva Pharmaceutical Industries voluntarily recalled 8 lots of a cancer drug a couple of months ago after rubber particles were found in some containers. Now the generics maker says the problem is more widespread than it first thought and more units will need to be retrieved.

Avista Pharma snaps up NC manufacturing facility from rival Scynexis

Avista Pharma Solutions has snapped up the manufacturing, development and animal health services business from rival Scynexis in a move designed to bulk up its capacity and garner a larger share of the growing market.

EU ban on more than 700 drugs set for Aug. 21

The European Union will impose a ban starting Aug. 21 on more than 700 drugs that were bioequivalency tested by India's GVK BioSciences after inspectors raised questions about its procedures.

Lupin gets first U.S. manufacturing base with buyout of GAVIS

India's Lupin has landed its first manufacturing site in the U.S. with an $880 million deal to buy a small generics maker in New Jersey that specializes in niche products including dermatology controlled substances.

MORE NEWS